Hefei Lifeon Pharmaceutical Future Growth
Future criteria checks 3/6
Hefei Lifeon Pharmaceutical is forecast to grow earnings and revenue by 24.6% and 17.7% per annum respectively. EPS is expected to grow by 24.8% per annum. Return on equity is forecast to be 13.5% in 3 years.
Key information
24.6%
Earnings growth rate
24.8%
EPS growth rate
| Pharmaceuticals earnings growth | 18.7% |
| Revenue growth rate | 17.7% |
| Future return on equity | 13.5% |
| Analyst coverage | Low |
| Last updated | 26 Sep 2024 |
Recent future growth updates
No updates
Recent updates
Why Hefei Lifeon Pharmaceutical's (SZSE:003020) Shaky Earnings Are Just The Beginning Of Its Problems
Nov 05
Hefei Lifeon Pharmaceutical (SZSE:003020) Has A Somewhat Strained Balance Sheet
Sep 30Hefei Lifeon Pharmaceutical (SZSE:003020) Has Announced A Dividend Of CN¥0.50
May 23Investors Still Aren't Entirely Convinced By Hefei Lifeon Pharmaceutical Co., Ltd.'s (SZSE:003020) Earnings Despite 25% Price Jump
May 22Hefei Lifeon Pharmaceutical's (SZSE:003020) Profits May Not Reveal Underlying Issues
Apr 29Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2,206 | 306 | N/A | 386 | 1 |
| 12/31/2025 | 1,833 | 242 | N/A | 302 | 1 |
| 12/31/2024 | 1,551 | 196 | N/A | 155 | 1 |
| 9/30/2024 | 1,501 | 174 | 106 | 268 | N/A |
| 6/30/2024 | 1,402 | 173 | 42 | 222 | N/A |
| 3/31/2024 | 1,423 | 191 | 12 | 198 | N/A |
| 12/31/2023 | 1,901 | 227 | 6 | 204 | N/A |
| 9/30/2023 | 2,210 | 210 | -117 | 138 | N/A |
| 6/30/2023 | 2,618 | 242 | -144 | 129 | N/A |
| 3/31/2023 | 2,763 | 228 | -48 | 208 | N/A |
| 1/1/2023 | 2,579 | 209 | -46 | 201 | N/A |
| 9/30/2022 | 2,503 | 217 | -2 | 167 | N/A |
| 6/30/2022 | 2,429 | 187 | 64 | 249 | N/A |
| 3/31/2022 | 2,353 | 178 | -48 | 165 | N/A |
| 12/31/2021 | 2,273 | 172 | -28 | 159 | N/A |
| 9/30/2021 | 2,183 | 161 | -41 | 134 | N/A |
| 6/30/2021 | 2,076 | 153 | -7 | 115 | N/A |
| 3/31/2021 | 1,991 | 148 | 91 | 163 | N/A |
| 12/31/2020 | 1,894 | 135 | 116 | 172 | N/A |
| 9/30/2020 | 1,809 | 127 | 161 | 205 | N/A |
| 6/30/2020 | 1,758 | 120 | 158 | 201 | N/A |
| 3/31/2020 | 1,711 | 109 | 100 | 143 | N/A |
| 12/31/2019 | 1,650 | 105 | 105 | 149 | N/A |
| 12/31/2018 | 1,425 | 92 | 35 | 64 | N/A |
| 12/31/2017 | 1,167 | 77 | N/A | 11 | N/A |
| 12/31/2016 | 1,028 | 67 | N/A | 59 | N/A |
| 12/31/2014 | 962 | 54 | N/A | 92 | N/A |
| 12/31/2013 | 878 | 47 | N/A | 36 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 003020's forecast earnings growth (24.6% per year) is above the savings rate (2.8%).
Earnings vs Market: 003020's earnings (24.6% per year) are forecast to grow slower than the CN market (26.3% per year).
High Growth Earnings: 003020's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 003020's revenue (17.7% per year) is forecast to grow faster than the CN market (13.9% per year).
High Growth Revenue: 003020's revenue (17.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 003020's Return on Equity is forecast to be low in 3 years time (13.5%).